Wat is de prijs voor Ortin Laboratories Limited (ORTINLAB)

Het prijs van Ortin Laboratories Limited (ORTINLAB) is $0.2488447

Wat is de marktkapitalisatie voor Ortin Laboratories Limited (ORTINLAB)

Marktkapitalisatie voorOrtin Laboratories Limited (ORTINLAB) is $2.01M

Ortin Laboratories Limited (ORTINLAB) Operationele Marge

Ortin Laboratories Limited, a pharmaceutical company established in Hyderabad, India, in 1986, is engaged in the manufacturing and commercialization of a diverse range of medicines, drugs, and chemical intermediates. The company provides a wide array of pharmaceutical formulations, presented as tablets, capsules, syrups, and dry powders. These products target various therapeutic domains such as metabolic diseases (e.g., anti-diabetics), allergic reactions, infections (including broad-spectrum antibiotics and antifungals like quinolones, penicillins, cephalosporins, macrolides, and antifungals), pain management and fever reduction (analgesics and antipyretics), cardiovascular ailments (anti-anginal and cardiovascular products), digestive system disorders (antacids and anti-ulcerants), neurological and psychiatric conditions (sedatives, tranquilizers, psychiatry products), and nutritional supplementation (like vitamins, calcium, iron, and protein supplements). Specialized offerings also include anti-retroviral, anti-arthritic, anti-helminthic, anti-spasmodic, gynaec, appetite stimulators, and chemotherapeutic preparations. In addition to finished pharmaceuticals, Ortin produces active pharmaceutical ingredient (API) intermediates for applications such as anti-retrovirals, anti-diabetics, pain and fever medications, antibiotics, antifungals, antacids, anti-malarials, and anti-ulcerants. Its manufacturing capabilities also extend to fine chemicals and Grignard/alkali metal compounds. The company offers specialized services covering process development and characterization, analytical research, assay development, and product characterization. It also contributes to diagnostics through the development of rapid flow kits, assays, and reagents. Ortin Laboratories undertakes long-term contracts for the production of intermediates and the creation of novel APIs. Moreover, it actively functions as a merchant exporter of its finished pharmaceutical products.

Jaar	Operationele Marge	Wijzigen
2026 (TTM)	-989.65%	208.87%
2024	-320.41%	-7,220.22%
2023	4.50%	15.98%
2022	3.88%	-66.98%
2021	11.75%	505.67%
2020	1.94%	-35.76%
2019	3.02%	-36.02%
2018	4.72%	95.85%
2017	2.41%	-31.34%
2016	3.51%	3.24%
2015	3.40%	14.48%
2014	2.97%	-5.71%
2013	3.15%	3.62%
2012	3.04%	-10.32%
2011	3.39%	-18.31%
2010	4.15%	24.62%
2009	3.33%	-35.09%
2008	5.13%	0.00%

Jaar

Operationele Marge

Wijzigen

2026 (TTM)

-989.65%

208.87%

2024

-320.41%

-7,220.22%

2023

4.50%

15.98%

2022

3.88%

-66.98%

2021

11.75%

505.67%

2020

1.94%

-35.76%

2019

3.02%

-36.02%

2018

4.72%

95.85%

2017

2.41%

-31.34%

2016

3.51%

3.24%

2015

3.40%

14.48%

2014

2.97%

-5.71%

2013

3.15%

3.62%

2012

3.04%

-10.32%

2011

3.39%

-18.31%

2010

4.15%

24.62%

2009

3.33%

-35.09%

2008

5.13%

0.00%

Bedrijf	Operationele Marge	Verschil in operationele marge	Land
MERCK Kommanditgesellschaft auf Aktien MER.SW	0.00%	-	DE
Merck KGaA MRK.DE	0.00%	-	DE
Takeda Pharmaceutical Company Limited 4502.T	0.00%	-	JP
Galderma Group AG GALD.SW	0.00%	-	CH
Sun Pharmaceutical Industries Limited SUNPHARMA.NS	22.93%	-100.02%	IN

Bedrijf

Operationele Marge

Verschil in operationele marge

Land